EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Intraperitoneal transplant of Hepatocytes co-Encapsulated with mesenchymal stromal cells in modified alginate microbeads for the treatment of acute Liver failure in Pediatric patients (HELP)—An open-label, single-arm Simon’s two stage phase 1 study protocol

Emer Fitzpatrick, Celine Filippi, Barath Jagadisan iD, Dharshene Shivapatham, Hanish Anand, Mike Lyne, Katherine-Daisy Stroud, Rebecca Newton, Marc DeLord, Abdel Douiri, Anil Dhawan

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0288185 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS ONE, 2023. Verfasst von Emer Fitzpatrick und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Liver GI and Nutrition Centre and Mowat Labs, King's College Hospital, London, United Kingdom. Hauptthemen laut MEDLINE: Liver Failure, Acute, Liver Transplantation, Mesenchymal Stem Cells. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pediatric acute liver failure (PALF) carries a high mortality without liver transplantation (LT) in children. Liver transplantation, though lifesaving, is limited by timely donor organ availability, the risks of major surgery and complications of life-long immunosuppression. Hepatocyte transplantation (HT) improves synthetic and detoxification functions in small animal models. The encapsulation of hepatocytes in alginate protects it from the recipient immune system while the intraperitoneal route of administration allows large volumes to be infused. The safety and possibly short-term efficacy of encapsulated hepatocytes has been observed in a named patient use. A novel type of microbeads (HMB002) has been developed, using a modified alginate and mesenchymal stromal cells (MSCs). Its safety and medium-term efficacy need to be studied in the context of clinical study while optimizing the hepatocyte function and viability using modifications of the alginate and MSCs co-encapsulation.

Methods

A single centre, non-randomised, open-label, single-arm Simon’s two stage study will be conducted to evaluate the safety, biological activity and tolerability of transplantation of a single intraperitoneal dose of microbeads made from an optimum combination of a modified alginate, MSCs and hepatocytes in 17 patients less than 16 years of age with acute liver failure (Stage 1: 9 patients and Stage 2: 8 patient). Safety will be assessed by documenting moderate to severe (including life threatening and death) adverse events due to HMB002 in the first 52 weeks post-procedure. Tolerability will be assessed by observing the proportion of initiated infusions where >80% of infusion is received by the patient. Biological activity will be reflected in patient survival with native liver at 24 weeks post treatment.

Discussion

HMB002, if safe and efficacious in acute liver failure, could be a bridge until the liver regenerates or a suitable organ becomes available. There are multiple advantages to using HT. HT, when delivered by the intraperitoneal route, is less invasive than LT. Hepatocytes from a single donor liver can be used to treat multiple patients. Cryopreserved cells provide an off-the-shelf emergency treatment in PALF. When encapsulated, alginate encapsulation of hepatocytes precludes the need for immunosuppression unlike in LT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver Failure, AcuteLiver TransplantationMesenchymal Stem CellsHumansAlginatesClinical Trials, Phase I as TopicHepatocytesLiving DonorsMicrospheresChild

Substanzen

Alginates

Autor:innen und Institutionen

  • Pediatric Liver GI and Nutrition Centre and Mowat Labs, King's College Hospital, London, United Kingdom.
  • King's College London, London, United Kingdom.
  • Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom.
  • King's Health Partners Clinical Trials Office, London, United Kingdom.
  • School of Population Health and Environmental Sciences, King's College London, London, United Kingdom.

ORCID-Profile: Barath Jagadisan

Förderung

  • Medical Research Council
  • Department of Health

Zitieren

APA

Fitzpatrick, E., Filippi, C., Jagadisan, B., Shivapatham, D., Anand, H., Lyne, M., Stroud, K. D., Newton, R., DeLord, M., Douiri, A., & Dhawan, A. (2023). Intraperitoneal transplant of Hepatocytes co-Encapsulated with mesenchymal stromal cells in modified alginate microbeads for the treatment of acute Liver failure in Pediatric patients (HELP)—An open-label, single-arm Simon’s two stage phase 1 study protocol. PLOS ONE. https://doi.org/10.1371/journal.pone.0288185

Vancouver

Fitzpatrick E, Filippi C, Jagadisan B, Shivapatham D, Anand H, Lyne M, et al. Intraperitoneal transplant of Hepatocytes co-Encapsulated with mesenchymal stromal cells in modified alginate microbeads for the treatment of acute Liver failure in Pediatric patients (HELP)—An open-label, single-arm Simon’s two stage phase 1 study protocol. PLOS ONE. 2023. doi:10.1371/journal.pone.0288185

BibTeX
@article{Fitzpatrick2023,
  author = {Fitzpatrick, Emer and Filippi, Celine and Jagadisan, Barath and Shivapatham, Dharshene and Anand, Hanish and Lyne, Mike and Stroud, Katherine-Daisy and Newton, Rebecca and DeLord, Marc and Douiri, Abdel and Dhawan, Anil},
  title = {Intraperitoneal transplant of Hepatocytes co-Encapsulated with mesenchymal stromal cells in modified alginate microbeads for the treatment of acute Liver failure in Pediatric patients (HELP)—An open-label, single-arm Simon’s two stage phase 1 study protocol},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0288185}
}
Kostenlos starten →